Extensive-stage Small-cell Lung Cancer Clinical Trials in Chicago, Illinois
5 recruitingChicago, Illinois
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled158 locationsNCT07005128
Recruiting
Phase 2
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Muhammad Furqan30 enrolled5 locationsNCT04699838
Recruiting
Phase 1
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Extensive-stage Small-cell Lung Cancer
Amgen220 enrolled31 locationsNCT06598306
Recruiting
Phase 2
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
Lung CancerSmall Cell Lung CancerExtensive-stage Small-cell Lung Cancer
University of Chicago49 enrolled2 locationsNCT05068232
Recruiting
Phase 1Phase 2
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Extensive-stage Small-cell Lung Cancer
Daiichi Sankyo123 enrolled58 locationsNCT06362252